Search

Displaying results 2761 - 2770 of 10000 in total
  1. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.

    Categories: Amino Acids and Derivatives, Alimentary Tract and Metabolism
  2. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162] … [L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013

    Categories: Sex Hormones and Insulins
  3. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils

    Categories: Antineoplastic and Immunomodulating Agents, Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  4. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    immune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can occasionally be fatal. … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]

    Categories: Antineoplastic and Immunomodulating Agents
  5. Indication

    Acute Myeloid Leukemia

    go.drugbank.com/conditions/DBCOND0029883
    Drugs: Azacitidine · Cedazuridine · Cyclophosphamide · Cytarabine · Decitabine · Doxorubicin +9 more
    Synonyms: Refractory anemia with excess blasts in transformation, Refractory anaemia with excess blasts in transformation
  6. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    of an adjuvant. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  7. Target

    Serine/threonine-protein kinase Nek11

    go.drugbank.com/bio_entities/BE0004758
    TargetHumans

    Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. … Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation

    Synonyms: Never in mitosis A-related kinase 11
  8. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    , and a longer half-life, making it an attractive candidate for oral dosing. … by Alkermes Inc.

    Categories: olanzapine and samidorphan, Diazepines, Oxazepines, Thiazepines and Oxepines
  9. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and

    Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Compounds used in a research, industrial, or household setting
  10. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated

    Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaCategories: Antineoplastic and Immunomodulating Agents